Cannabidiol and Amisulpride Improve Cognition in Acute Schizophrenia in an Explorative, Double-Blind, Active-Controlled, Randomized Clinical Trial
Cannabidiol (CBD), a principal phytocannabinoid constituent, has demonstrated antipsychotic properties in recent clinical trials. While it has also been suggested a promising candidate for the treatment of neurodegenerative disorders, it failed to demonstrate efficacy in cognitive impairments associ...
Saved in:
Main Authors: | F. Markus Leweke (Author), Cathrin Rohleder (Author), Christoph W. Gerth (Author), Martin Hellmich (Author), Ralf Pukrop (Author), Dagmar Koethe (Author) |
---|---|
Format: | Book |
Published: |
Frontiers Media S.A.,
2021-04-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Cannabidiol as a potential new type of an antipsychotic. A critical review of the evidence
by: Cathrin Rohleder, et al.
Published: (2016) -
Population pharmacokinetics of Amisulpride in Chinese patients with schizophrenia with external validation: the impact of renal function
by: Anning Li, et al.
Published: (2023) -
Cannabidiol, cognition and schizophrenia: a narrative review
by: Trevor R. Norman
Published: (2024) -
Amisulpride in Refractory Behavioral and Psychological Symptoms of Dementia
by: Vikas Dhikav, et al.
Published: (2017) -
Modeling and Simulation for Individualized Therapy of Amisulpride in Chinese Patients with Schizophrenia: Focus on Interindividual Variability, Therapeutic Reference Range and the Laboratory Alert Level
by: Huang S, et al.
Published: (2021)